1,3- dimethyl- 1,3- bis(4- fluorophenyl)- 1,3- bis(3- (1- (4- butypiperazinyl))propyl)disiloxane

structure in first source

Also Known As:

1,3-dimethyl-1,3-bis(4-fluorophenyl)-1,3-bis(3-(1-(4-butypiperazinyl))propyl)disiloxane tetrahydrochloride; SILA 421

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - 1,3-dimethyl-1,3-bis(4-fluorophenyl)-1,3-bis(3-(1-(4-butypiperazinyl))propyl)disiloxane: 3
Inorganic Chemicals: 9
- Silicon Compounds: 11
  - Siloxanes: 98
    - 1,3-dimethyl-1,3-bis(4-fluorophenyl)-1,3-bis(3-(1-(4-butypiperazinyl))propyl)disiloxane: 3
Organic Chemicals: 133
- Organosilicon Compounds: 15
  - Siloxanes: 98
    - 1,3-dimethyl-1,3-bis(4-fluorophenyl)-1,3-bis(3-(1-(4-butypiperazinyl))propyl)disiloxane: 3
Macromolecular Substances: 97
- Polymers: 13051
  - Siloxanes: 98
    - 1,3-dimethyl-1,3-bis(4-fluorophenyl)-1,3-bis(3-(1-(4-butypiperazinyl))propyl)disiloxane: 3
Biomedical and Dental Materials
- Polymers: 13051
  - Siloxanes: 98
    - 1,3-dimethyl-1,3-bis(4-fluorophenyl)-1,3-bis(3-(1-(4-butypiperazinyl))propyl)disiloxane: 3
Technology, Industry, and Agriculture
- Manufactured Materials
  - Biomedical and Dental Materials
    - Polymers: 13051
      - Siloxanes: 98
        1,3-dimethyl-1,3-bis(4-fluorophenyl)-1,3-bis(3-(1-(4-butypiperazinyl))propyl)disiloxane: 3

1.	Extensively Drug-Resistant Tuberculosis 05/01/2009 - "Because SILA 421 revealed good in vitro and ex vivo activities and is devoid of any cytotoxic activity, it is a potential candidate as an anti-MDR/XDR-TB drug." 05/01/2009 - "Amongst the two compounds tested, SILA 421 was shown to have in vitro activity against XDR-TB (MIC<3.5mg/L) and to transform non-killing macrophages into effective killers of phagocytosed bacteria, without any cytotoxic activity. " 05/01/2009 - "SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB)."
2.	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 05/01/2013 - "Activity of the efflux pump inhibitor SILA 421 against drug-resistant tuberculosis."
3.	Neoplasms (Cancer) 05/01/2009 - "SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB)."
4.	Leukemia 07/01/2012 - "HL-60 leukemia and MDA-MB-435 breast cancer cells exhibited cell cycle arrest and apoptotic cell death in response to SILA 421. "
5.	Breast Neoplasms (Breast Cancer) 07/01/2012 - "HL-60 leukemia and MDA-MB-435 breast cancer cells exhibited cell cycle arrest and apoptotic cell death in response to SILA 421. "